Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
Benedetta Maria Bonora, Angelo Avogaro, Gian Paolo Fadini Department of Medicine, University of Padova, Padova 35128, ItalyCorrespondence: Gian Paolo FadiniDepartment of Medicine, University of Padova, Via Giustiniani 2, Padova 35128, ItalyTel +39 49 8214318Fax +29 49 8212184Email gianpaolo.fadini@u...
Guardado en:
Autores principales: | Bonora BM, Avogaro A, Fadini GP |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/57add5ecf2e84f1399d0d1489b66b187 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Santos Cavaiola T, et al.
Publicado: (2018) -
Comparison of the changes in the factors associated with the renal prognosis of non-elderly and elderly subjects treated with empagliflozin- a retrospective observation study in Japanese patients with type 2 diabetes
por: Ito H, et al.
Publicado: (2019) -
Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
por: Fan Yang, et al.
Publicado: (2020) -
Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy
por: David Bobrowski, et al.
Publicado: (2021) -
SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients
por: Vladimir V Salukhov, et al.
Publicado: (2021)